Finding the right KIT inhibitor for advanced systemic mastocytosis
- PMID: 34873346
- DOI: 10.1038/s41591-021-01588-z
Finding the right KIT inhibitor for advanced systemic mastocytosis
Comment on
-
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.Nat Med. 2021 Dec;27(12):2192-2199. doi: 10.1038/s41591-021-01539-8. Epub 2021 Dec 6. Nat Med. 2021. PMID: 34873345 Free PMC article.
-
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.Nat Med. 2021 Dec;27(12):2183-2191. doi: 10.1038/s41591-021-01538-9. Epub 2021 Dec 6. Nat Med. 2021. PMID: 34873347 Free PMC article. Clinical Trial.
References
-
- Valent, P., Akin, C. & Metcalfe, D. D. Blood 129, 1420–1427 (2017). - DOI
-
- Metcalfe, D. D. J. Invest. Dermatol. 96, 2S–4S (1991). - DOI
-
- Castells, M. & Austen, K. F. Int. Arch. Allergy Immunol. 127, 147–152 (2002). - DOI
-
- Theoharides, T. C., Valent, P. & Akin, C. N. Engl. J. Med. 373, 163–172 (2015). - DOI
-
- Escribano, L., Akin, C., Castells, M., Orfao, A. & Metcalfe, D. D. Ann. Hematol. 81, 677–690 (2002). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
